Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't know if they initiated a "buy" but they list BHRT as a stock they make a market in.
Maxim
It's time. NASDAQ.
Awesome. This is great news for BHRT IMO.
Phase 2 for Adipocell coming soon IMO
http://www.bioheartinc.com/AboutUs/Overview
Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells. In collaboration with the Regenerative Medicine Institute in Tijuana, Mexico, congestive heart failure patients are being treated in a Phase I/II trial at Hospital Angeles in Tijuana. Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy. The therapy involves the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. Transplantation of AdipoCell™ is accomplished through endocardial implantations with an injection catheter.
https://mobile.twitter.com/BioheartInc
We have recently applied to begin #trials using #stemcells derived from the patient’s own fat. bit.ly/1vYBRu9 pic.twitter.com/xUAJyNhlvd
http://www.sciencecodex.com/new_treatments_for_cancer_diabetes_and_heart_disease_you_may_have_a_pig_to_thank-146217
BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, M.D., Chief Scientific Officer, Advanced Cell Technology, Inc.
Nice!
You mean no one wants to sell at the bid price... That's completely understandable IMO. My shares are worth a lot more than a low bid.
http://investorstemcell.com/sector/10249/
On dollars and cents, Bioheart has achieved a number of significant financial milestones in 2014. Most importantly, we have increased revenue through international Myocath sales, proprietary stem cell culturing, laboratory kits, as well as physician training throughout the world. Below is a brief summary of financial spotlights:
· – our YTD Revenue increased from $56,000 to $1.6m, 2013 vs. 2014.
· – 3Q Revenue up from $32,000 to $580,000, 2013 vs. 2014.
· – Current liabilities were reduced 23% from $13.4m to $10.3m YTD. This was accomplished by debt to equity conversion at $0.04 as well as debt limitations under Florida law.
· – Working capital deficit improved by 24% from $13.4m to $10m YTD
· – YTD net actual loss down 48% from $2.4m to $1.2m year-over-year.
· – Launched joint ventures in South Africa, Australia, Honduras, Azerbaijan and Columbia.
· – Cash used in operating activities down 52%: $747,000 in YTD 2014 as compared to $1.6m in YTD 2013.
· – $3 million Equity Enhancement Program (“EEP”) with a Magna affiliate fund, Magna Equities II, LLC.
Please view the most recent 10Q here. http://www.bioheartinc.com/Investors/SECFilings
- See more at: http://investorstemcell.com/sector/10249/#sthash.nwz9UTBT.dpuf
http://ir.ocata.com/press-releases/detail/2654
http://www.heraldonline.com/2014/11/24/6559814/ocata-therapeutics-receives-advanced.html?sp=/100/773/385/
http://www.streetinsider.com/Press+Releases/Ocata+Therapeutics+Receives+Advanced+Therapy+Medicinal+Product+Designation+from+the+European+Medicines+Agency/10043241.html
http://news.investors.com/newsfeed-business-wire/112414-141626643-ocata-therapeutics-receives-advanced-therapy-medicinal-product-designation-from-the-european-medicines-agency.aspx
http://investorstemcell.com/sector/10249/
New CEO Blog.
Thanks ISC!
I'll tell you exactly what it says. It says Magna will give BioHeart up to 3 MILLION dollars to continue its pipeline progress. Forget dilution... A stocks PPS is based on what a buyer is willing to pay. So let me ask you a simple question. What do you believe BioHeart's PPS should be or how much would you pay per share of a company that is a phase 3 leader in the field of regenerative medicine (IMO could be the next boom once the field treatment is approved), has already penetrated markets worldwide and has continual revenue increase quarter over quarter as well as a top notch leadership team with a proven track record (I'll leave the DD up to you) good luck.
Can you provide an example of the "destruction" that you speak of??
Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
Read more at http://www.stockhouse.com/news/press-releases/2014/11/17/bioheart-announces-expansion-of-clinical-study-for-degenerative-disc-disease#KtfADV0JRf81bJIv.99
Sunrise, FL / Accesswire / November 17, 2014 / Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will expand to a second clinical site to enroll patients in the study for degenerative disc disease (DDD). The study will enroll up to 100 patients to determine the safety and efficacy of adipose derived stem cells or AdipoCell(TM) in patients with DDD.
Robert Silbert, MD of Physical Medicine/ Rehab Associates in Indianapolis, Indiana is the principal investigator for the study and has been enrolling patients for approximately 6 months. Julian Robert Gershon Jr., DO, FAOASM, ABAARM and the team at Aspen Institute for Antiaging & Regenerative Medicine will now enroll patients at the center in Aspen, CO.
Bioheart has initiated this new study for DDD which will include a randomized control arm. The study has been reviewed and approved by the Institutional Review Board (IRB) of the International Cellular Medicine Society (ICMS). The ICMS IRB is committed to providing peer review of proposed studies of cell-based medical therapies based upon appropriate clinical translation, patient care and sa
Read more at http://www.stockhouse.com/news/press-releases/2014/11/17/bioheart-announces-expansion-of-clinical-study-for-degenerative-disc-disease#KtfADV0JRf81bJIv.99
What do you think about the competition not meeting phase 2 trial primary endpoints? (NeoStem)
“Bioheart has under promised and over delivered on their MyoCell technology for treating advanced heart failure. Their goal was to beat the performance of CHF drugs and CRT pacers that achieve respectively minus 4 meters decline and 16 to 20 meters improvement in exercise capacity. Bioheart’s 1st gen. MyoCell came in at 95.7 meters improvement over placebo in the controlled, randomized, double blinded Phase II/III MARVEL part I clinical trial - with 33 U.S. centers*. Now entrolling patients in the Phase III MIRROR Trial. No other cell type has beat 63 meters improvement. Cardiac and adipose derived cells score at about 53 meters improvement. Allogenic bone marrow derived cells achieve only 10 meters improvement.” Howard Leonhardt, Executive Chairman of Leonhardt Ventures commented “The 2nd generation Bioheart MyoCell SDF-1 with repeat delivery, nutrient hydrogel and electrical stimulation support is expected to provide even superior results, based on over a dozen years of pre-clinical studies. Bioheart’s MyoCell is the only cell type that has demonstrated an ability to form new contractile muscle in the depths of heart scar tissue. There is over $8 billion spent on CHF drugs each year providing no improvement and only slowing down slightly decline. What is needed is a product like Bioheart’s MyoCell and MyoCell SDF-1 designed to convert heart scar tissue to beating muscle and thus providing true strong improvement. “
https://www.prbuzz.com/business-entrepreneur/268787-leonhardt-increases-stake-in-bioheart-inc-1.html#.VGuZ0T59CWs.linkedin
Awesome!
Awesome.
Too many different yellow journalist trying to hold Ocata down... That article was complete garbage. I only posted to remind us what we're up against. Ocata will succeed, the stock price will rise again and soon IMO.
Just wanted to ask what you thought of, or if you knew anything about what one of BioHearts latest Twitter post pertains to?
It states as follows:
"BioHeart recently acquired a venture that focuses on regenerative medicine for animals. And there are at least six or seven other companies that are quite advanced, including one for ocular medicine."
https://mobile.twitter.com/BioheartInc
We believe in the power of vision. Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT, formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technologies. The company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration. Ocata’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Www.ocata.com
It's a beautiful slide and site.... I'm really digging the new logo. Ocata.
The Meaning of Ocata
The word “Ocata” is a Native American name for “healer”. Healing implies repair and regeneration – not merely slowing the progression of an inevitable disease. In the case of Regenerative Ophthalmology, it allows us to imagine therapies in which we replace diseased or damaged cells in the eye with healthy new cells and restore function and vision to the eye.
Ocata.com
Nice find. Did the site launch today?
You can't spell OCATA without an A, C and a T.
The JAX researchers collaborated with scientists at Genome Institute of Singapore, Advanced Cell Technologies in Marlborough, Mass., Brigham and Women's Hospital of Harvard Medical School in Boston, National University Health System in Singapore and the University of Connecticut Health Center in Farmington, Conn. The work was supported by grants from the Joint Council Office of the Agency for Science Technology Research (ASTAR) in Singapore, the U.S. Defense Advanced Research Project Agency, the Johnson & Johnson ASTAR Joint Program and Connecticut Innovations.
http://www.eurekalert.org/pub_releases/2014-11/jl-jlr111214.php
Exactly. All this and the revenues!!
1.5 million for the 3 quarters ending September 2014! 1 quarter still left to report!
Compared to only 56K in 2013!
That's roughly 27 X (times) more revenue so far in 2014 compared to 2013!! Looking forward to huge 10K!!
Hardly anything! That kind of discount in a store wouldn't even cover taxes!!!
BIOHEART, INC. COMPLETES FINANCING WITH MAGNA
October 24, 2014
http://www.bioheartinc.com/assets/press/MagnaPressRelease.pdf
Heres a good read about BioHeart
http://investorstemcell.com/investing/your-doctor-wants-you-to-be-rich-and-not-die-of-heart-disease/
Their*